$RNAZNot financial advice.
NASDAQ:RNAZ IS trying hard to get out of this broadening formation. multi time frame is all bullish. will see if it goes thru or gets rejected at top!
Subscribe and like for more ideas.
Thanks!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−8.0556 USD
−18.55 M USD
0.00 USD
17.24 M
About TransCode Therapeutics, Inc.
Sector
Industry
CEO
Thomas A. Fitzgerald
Website
Headquarters
Newton
Founded
2016
FIGI
BBG00ZGYHV03
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.
$RNAZ is gonna fall todayPupm&Dump trading strategy idea.
$RNAZ is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $7,85;
stop-loss — $8,47;
take-profit — $6,62.
Do not view th
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of RNAZ is 0.3845 USD — it has increased by 1.18% in the past 24 hours. Watch TransCode Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TransCode Therapeutics, Inc. stocks are traded under the ticker RNAZ.
RNAZ stock has risen by 13.29% compared to the previous week, the month change is a −38.97% fall, over the last year TransCode Therapeutics, Inc. has showed a −96.16% decrease.
We've gathered analysts' opinions on TransCode Therapeutics, Inc. future price: according to them, RNAZ price has a max estimate of 3.00 USD and a min estimate of 3.00 USD. Watch RNAZ chart and read a more detailed TransCode Therapeutics, Inc. stock forecast: see what analysts think of TransCode Therapeutics, Inc. and suggest that you do with its stocks.
RNAZ reached its all-time high on Jul 9, 2021 with the price of 5,600.0000 USD, and its all-time low was 0.2160 USD and was reached on Aug 14, 2024. View more price dynamics on RNAZ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RNAZ stock is 8.53% volatile and has beta coefficient of 1.95. Track TransCode Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is TransCode Therapeutics, Inc. there?
Today TransCode Therapeutics, Inc. has the market capitalization of 6.56 M, it has increased by 11.86% over the last week.
Yes, you can track TransCode Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TransCode Therapeutics, Inc. is going to release the next earnings report on Mar 28, 2025. Keep track of upcoming events with our Earnings Calendar.
RNAZ net income for the last quarter is −2.32 M USD, while the quarter before that showed −5.19 M USD of net income which accounts for 55.28% change. Track more TransCode Therapeutics, Inc. financial stats to get the full picture.
No, RNAZ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 10.00 employees. See our rating of the largest employees — is TransCode Therapeutics, Inc. on this list?
Like other stocks, RNAZ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TransCode Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TransCode Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TransCode Therapeutics, Inc. stock shows the sell signal. See more of TransCode Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.